Seeking Blue Revisit
We developed an investment thesis based on the discounted cash flow valuations of some of the most credit worthy companies in the S&P 500. All of them blue chips, trading at substantial discounts to their net worth, we called this “Seeking Blue”. You can see our original analysis at http://workshops.saxangle.com/seeking-blue/. We decided to revisit this valuation. The bottom line is that many of these companies remain substantially undervalued. And this is with our pessimistic scenario of zero growth and pressure on operating margins. The results from July 18,2012 are below: Description Ticker Price 7/18/12 5/3/13 Change Pfizer PFE $23.14 $28.96 … Read more